DashboardPortfoliosWatchlistCommunityDiscoverScreener
Loading...
  • Community
  • /
  • Sweden
  • /
  • Pharmaceuticals & Biotech
  • /
  • AddLife
Back to narrative

AnalystConsensusTarget updated the narrative for ALIF B

ALIF B logo

Optimized Product Portfolio And Acquisitions Will Deliver Future Value

ALIF B logo
ALIF B
A
AnalystConsensusTarget
AnalystConsensusTarget
Not Invested
Published 18 Mar 2025
9 viewsusers have viewed this narrative update

Update shared on 20 Sep 2025

Fair value Increased 1.78%
PreviousNext
26 Apr
SEK 153.30
AnalystConsensusTarget's Fair Value
SEK 190.00
19.3% undervalued intrinsic discount
1Y
-18.0%
7D
-5.9%
Loading
1Y
-18.0%
7D
-5.9%

Despite a slight decrease in consensus revenue growth forecasts, AddLife’s fair value estimate was marginally raised, with the analyst price target increasing from SEK196.50 to SEK200.00.


Valuation Changes


Summary of Valuation Changes for AddLife

  • The Consensus Analyst Price Target remained effectively unchanged, moving only marginally from SEK196.50 to SEK200.00.
  • The Consensus Revenue Growth forecasts for AddLife has fallen from 5.9% per annum to 5.6% per annum.
  • The Future P/E for AddLife remained effectively unchanged, moving only marginally from 37.34x to 37.92x.

Have other thoughts on AddLife?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

Comments

0 comments

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Valuator
Company Info
Notes
AnalystConsensusTarget'sFair Value
SEK 200
23.3% undervalued intrinsic discount
Future estimation in
PastFuture012b20152017201920212023202520272028Revenue SEK 12.3bEarnings SEK 753.8m
Revenue
Profit Margin
Future PE
Growth p.a.
%
Decrease
Increase
Forecast revenue growth rate
6.02%
Historical revenue growth rate
6.62%
Life Sciences revenue growth rate
0.42%
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
%
0
Decrease
Increase
Current discount rate
6.72%
Calculation
SEK 753.76m
Earnings '28
x
37.92x
PE Ratio '28
=
SEK 28.58b
Market Cap '28
SEK 28.58b
Market Cap '28
/
121.86m
No. shares '28
=
SEK 234.53
Share Price '28
SEK 234.53 Share Price '28
Discounted to 2025 @ 5.70% p.a.
=
SEK 198.58
Fair Value '25